{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:22:56Z","timestamp":1792174976107,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.beem.2024.101928","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T05:03:37Z","timestamp":1724475817000},"page":"101928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Recent discoveries of Sino-Caucasian differences in the genetics of phaeochromocytomas and paragangliomas"],"prefix":"10.1016","volume":"38","author":[{"given":"Jingjing","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2024.101928_bib1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMra1806651","article-title":"Eng C pheochromocytoma and paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2024.101928_bib2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41574-023-00926-0","article-title":"Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement","volume":"20","author":"Ta\u00efeb","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2024.101928_bib3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"N\u00f6lting","year":"2022","journal-title":"Endocr Rev"},{"issue":"8","key":"10.1016\/j.beem.2024.101928_bib4","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-23-0021","article-title":"The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal","volume":"30","author":"Villa","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2024.101928_bib5","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1470-2045(10)70007-3","article-title":"SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma","volume":"11","author":"Bayley","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beem.2024.101928_bib6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrendo.2016.185","article-title":"Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas","volume":"13","author":"Toledo","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2024.101928_bib7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/jnci\/djab158","article-title":"Germline SUCLG2 Variants in Patients With Pheochromocytoma and Paraganglioma","volume":"114","author":"Hadrava Vanova","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.beem.2024.101928_bib8","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1001\/jamaoncol.2017.0223","article-title":"Clinical characterization of the pheochromocytoma and paraganglioma susceptibility genes SDHA, TMEM127, MAX, and SDHAF2 for gene-informed prevention","volume":"3","author":"Bausch","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.beem.2024.101928_bib9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beem.2024.101928_bib10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrendo.2009.250","article-title":"Paraganglioma syndrome type 1 in a patient with Carney-Stratakis syndrome","volume":"6","author":"Ayala-Ramirez","year":"2010","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2024.101928_bib11","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/cncr.31839","article-title":"Nonmosaic somatic HIF2A mutations associated with late onset polycythemia-paraganglioma syndrome: newly recognized subclass of polycythemia-paraganglioma syndrome","volume":"125","author":"Pang","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.beem.2024.101928_bib12","doi-asserted-by":"crossref","first-page":"R253","DOI":"10.1530\/ERC-11-0170","article-title":"Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas","volume":"18","author":"Welander","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2024.101928_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.trecan.2017.02.002","article-title":"Racial differences in cancer susceptibility and survival: more than the color of the skin?","volume":"3","author":"\u00d6zdemir","year":"2017","journal-title":"Trends Cancer"},{"key":"10.1016\/j.beem.2024.101928_bib14","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1161\/HYPERTENSIONAHA.114.03346","article-title":"Clinical characteristics of somatic mutations in Chinese patients with aldosterone-producing adenoma","volume":"65","author":"Zheng","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.beem.2024.101928_bib15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41698-019-0086-1","article-title":"Precision oncology of lung cancer: genetic and genomic differences in Chinese population","volume":"3","author":"Shen","year":"2019","journal-title":"NPJ Precis Oncol"},{"issue":"10","key":"10.1016\/j.beem.2024.101928_bib16","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa502","article-title":"Sino-European differences in the genetic landscape and clinical presentation of pheochromocytoma and paraganglioma","volume":"105","author":"Jiang","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101928_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.574662","article-title":"Genetic and clinical profiles of pheochromocytoma and paraganglioma: a single center study","volume":"11","author":"Ma","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.beem.2024.101928_bib18","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s12020-019-02075-9","article-title":"A nomogram for predicting the presence of germline mutations in pheochromocytomas and paragangliomas","volume":"66","author":"Su","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2024.101928_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2014.11.017","article-title":"Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes","volume":"33","author":"Martucci","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.beem.2024.101928_bib20","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1097\/PAS.0000000000000534","article-title":"Urinary bladder paragangliomas: how immunohistochemistry can assist to identify patients with SDHB germline and somatic mutations","volume":"39","author":"Giubellino","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.beem.2024.101928_bib21","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1210\/clinem\/dgac427","article-title":"Presentation, management, and outcomes of urinary bladder paraganglioma: results from a multicenter study","volume":"107","author":"Yu","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2024.101928_bib22","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/cen.15058","article-title":"Diagnosis and management of urinary bladder paragangliomas: a Sino-American-European retrospective observational study","volume":"101","author":"Pang","year":"2024","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2024.101928_bib23","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1056\/NEJMoa1205119","article-title":"Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia","volume":"367","author":"Zhuang","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2024.101928_bib24","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/hmg\/ddt069","article-title":"Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis","volume":"22","author":"Comino-M\u00e9ndez","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.beem.2024.101928_bib25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1530\/ERC-13-0384","article-title":"Frequent EPAS1\/HIF2\u03b1 exons 9 and 12 mutations in non-familial pheochromocytoma","volume":"21","author":"Welander","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2024.101928_bib26","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s12020-018-1617-1","article-title":"Molecular evaluation of a sporadic paraganglioma with concurrent IDH1 and ATRX mutations","volume":"61","author":"Zhang","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2024.101928_bib27","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1158\/1078-0432.CCR-16-2250","article-title":"Targeted exome sequencing of Krebs cycle genes reveals candidate cancer-predisposing mutations in pheochromocytomas and paragangliomas","volume":"23","author":"Remacha","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beem.2024.101928_bib28","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.beem.2024.101928_bib29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beem.2024.101928_bib30","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1210\/clinem\/dgac653","article-title":"Somatic IDH1 hotspot variants in Chinese patients with pheochromocytomas and paragangliomas","volume":"108","author":"Li","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101928_bib31","doi-asserted-by":"crossref","first-page":"E1266","DOI":"10.1210\/jc.2012-4257","article-title":"Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing","volume":"98","author":"Crona","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101928_bib32","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1210\/clinem\/dgac563","article-title":"Recurrent disease in patients with sporadic pheochromocytoma and paraganglioma","volume":"108","author":"Li","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101928_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.921645","article-title":"Mutational profile and potential molecular therapeutic targets of pheochromocytoma","volume":"13","author":"Ma","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.beem.2024.101928_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2599","article-title":"Epidemiological profile and clinical characteristics of 491 Brazilian patients with neurofibromatosis type 1","volume":"12","author":"Darrigo Junior","year":"2022","journal-title":"Brain Behav"},{"key":"10.1016\/j.beem.2024.101928_bib35","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/1078-0432.CCR-15-1841","article-title":"Recurrent mutations of chromatin-remodeling genes and kinase receptors in pheochromocytomas and paragangliomas","volume":"22","author":"Toledo","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beem.2024.101928_bib36","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s00268-017-4320-0","article-title":"Activating FGFR1 Mutations in Sporadic Pheochromocytomas","volume":"42","author":"Welander","year":"2018","journal-title":"World J Surg"},{"key":"10.1016\/j.beem.2024.101928_bib37","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/hmg\/dds374","article-title":"Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma","volume":"21","author":"Burnichon","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.beem.2024.101928_bib38","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1093\/hmg\/dds402","article-title":"Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas","volume":"21","author":"Welander","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.beem.2024.101928_bib39","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1210\/jc.2006-2833","article-title":"Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1","volume":"92","author":"Bausch","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101928_bib40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/cen.13163","article-title":"Pheochromocytoma and paraganglioma in patients with neurofibromatosis type 1","volume":"86","author":"Gruber","year":"2017","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2024.101928_bib41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ando.2020.01.001","article-title":"Prevalence and progression of carbohydrate disorders in patients with pheochromocytoma\/paraganglioma: retrospective single-center study","volume":"81","author":"Elenkova","year":"2020","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.beem.2024.101928_bib42","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41467-023-36769-6","article-title":"Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma","volume":"14","author":"Calsina","year":"2023","journal-title":"Nat Commun"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24001027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24001027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T23:01:02Z","timestamp":1737327662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X24001027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1521690X24001027"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2024.101928","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent discoveries of Sino-Caucasian differences in the genetics of phaeochromocytomas and paragangliomas","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2024.101928","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101928"}}